CompoAtlas

Vitamin B5 Synergistic 250 mg

Natural health product licensed in Canada

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Serratiopeptidase

Source : Serratia marcescens (E-15)

Potency : 0.498666667 FCC SU

0.000187 mgNot calculated
alpha-L-arabinofuranoside arabinofuranohydrolase

Source : Aspergillus niger - En entier

Potency : 0.0888 FCC HCU

0.000225 mgNot calculated
Protéase fongique

Source : Aspergillus niger - En entier

Potency : 0.152 FCC SAPU

0.07484 mgNot calculated
bêta-fructofuranosidase

Source : Saccharomyces spp.

Potency : 0.213325 FCC INVU

0.00325 mgNot calculated
myo-Inositol-hexakisphosphate 3-phosphohydrolase

Source : Aspergillus niger - En entier

Potency : 0.006675 FCC FTU

0.003325 mgNot calculated
Arthrospira platensis

Source : En entier

10 mgNot calculated
Arthrospira platensis

Source : Arthrospira platensis

10 mgNot calculated
Gelée royale

Source : Apis mellifera - sécrétion

Potency : 6 % 10-hydroxy-2-decenoic acid

10 mgNot calculated
Astragalus membranaceus

Source : Astragalus membranaceus - racine

Extraction ratio : 6:1

Dry plant equivalent : 12 mg

Potency : 16 % Polysaccharides

2 mgNot calculated
Poly(1-4-a-D-galacturonide)glycanohydrolase

Source : Aspergillus niger - En entier

Potency : 0.16 Endo-PGU

0.0016 mgNot calculated
Protéase fongique

Source : Aspergillus niger - En entier

Potency : 110.4975 FCC HUT

0.39916 mgNot calculated
Acide pantothénique

Source : d-panthothénate de calcium

250 mg250,000 µg
Vitamine C

Source : Acide ascorbique

200 mg200,000 µg
Vitamine C

Source : Vitamine C

200 mg200,000 µg
alpha-D-Galactoside galactohydrolase

Source : Aspergillus niger - En entier

Potency : 0.050675 FCC AGU

0.003375 mgNot calculated
4-alpha-D-glucane glucanohydrolase

Source : Aspergillus flavus var. oryzae - En entier

Potency : 31.4975 Unités d'alpha-amylase dextrinifiante du FCC

0.252 mgNot calculated
Bromélaïne de tige

Source : Tige(s)

Potency : 1,920 FCC PU

0.053325 mgNot calculated
4-(1,3;1,4)-bêta-D-glucane 4-glucanohydrolase

Source : Aspergillus niger - En entier

Potency : 3.36 FCC CU

0.028 mgNot calculated
1,4-alpha-D-Glucane glucohydrolase

Source : Aspergillus niger - En entier

Potency : 0.133325 FCC AGU

0.111125 mgNot calculated
bêta-D-galactoside galactohydrolase

Source : Aspergillus flavus var. oryzae - En entier

Potency : 11.450675 FCC ALU

0.0145 mgNot calculated
Triacylglycérol acylhydrolase

Source : Aspergillus niger - En entier

Potency : 5.3325 FCC LU

0.02 mgNot calculated
Diastase du malt

Source : Aspergillus niger - En entier

Potency : 0.3475 FCC DP

0.008675 mgNot calculated
papaïne

Source : Carica papaya, fruit

Potency : 800 FCC PU

0.008 mgNot calculated
Protéase bactérien

Source : Bacillus subtilis

Potency : 12 FCC PC

0.02495 mgNot calculated
Protéase bactérien

Source : En entier

Potency : 12 FCC PC

0.02495 mgNot calculated

Non-medicinal ingredients

Eau purifiée, Stéarate de magnésium, Hypromellose, Dioxyde de silicium

PopulationAgeQuantity per servingFrequency
AdultesNot specified1 Capsule1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Multi-vitamin supplement. Vitamin B5 is a factor in the maintenance of good health; helps the body to metabolize carbohydrates, fats and proteins; helps in tissue formation. Vitamin B5 supplementation helps to prevent Vitamin B5 deficiency. Vitamin C is a factor in the maintenance of good health; an antioxidant for the maintenance of good health; helps the body to metabolize fats and proteins; helps in the maintenance of bones, cartilage, teeth and gums; helps in wound healing. Vitamin C supplementation helps to prevent Vitamin C deficiency.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Product record

Licence holder
Vitazan Herbs and Vitamins Inc
NPN or DIN-HM
80053792
Status
Active licence
Licence date
11 September 2014
Revision date
Not provided
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80053792

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Serratiopeptidase
    Read the warning, when it applies and the studies cited

    SERRAPEPTASE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).

    Sources cited by Health Canada (4)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).

    Sources cited by Health Canada (4)
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial

    Known adverse reactions

    Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).

    Sources cited by Health Canada (1)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 25 July 2025

  • Gelée royale
    Read the warning, when it applies and the studies cited

    ROYAL JELLY

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Contraindications

    Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).

    Sources cited by Health Canada (8)
    • Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Case report
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
    • TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).

    Sources cited by Health Canada (6)
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report

    Health Canada monograph dated 24 April 2026

  • Astragalus membranaceus
    Read the warning, when it applies and the studies cited

    ASTRAGALUS - ASTRAGALUS MEMBRANACEUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an autoimmune disorder (Brinker 2010; Upton 1999).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Astragalus Root. Santa Cruz (CA): American Herbal Pharmacopoeia; 1999.

    Contraindications

    Condition of application: Traditional Chinese Medicine.

    Do not use if you have exterior excess, stagnation, yin deficiency or excess heat (Bensky et al. 2004; Chen and Chen 2004).

    Sources cited by Health Canada (2)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Health Canada monograph dated 30 May 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Vitamin B5 Synergistic 250 mg (Vitazan Herbs and Vitamins Inc): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80053792-vitamin-b5-synergistic-250-mg, updated 11 September 2014.

Enter to analyse, Shift+Enter for a new line